Member Info for TR64

world health organization

Dunnie France will not get any benefit from Ronapreve 10987 & 10933 Regeneron and combining them all fail ® and COV 2 2130 AND COV2196 both fail both are Evusheld by Astra Zeneca and they failed in all there trials. Astra are selling a mAb knowing it dose not work - Both fail against Omicrom . See sSlide 8.
https://investors.vir.bio/static-files/08bc6665-d0a9-4e86-b746-35ad88fa0235

Dunnie-India using Baricitinib a JAK -JAK 2 Inhibitor will cause VIPP
Baricitinib (Olumiant): risk of venous thromboembolism

£1.11 is fair value- debt out of control

Astra Monoclonal antibody fails against Omicon
https://investors.vir.bio/static-files/08bc6665-d0a9-4e86-b746-35ad88fa0235

GSK Prepares for De-Merger of Pharma and Consumer Healthcare

The year 2022 is expected to be transformative for GlaxoSmithKline. CEO Emma Walmsley noted that the pharma business and the consumer healthcare business's demerger is expected to "unlock tremendous value" for shareholders. Walmsley, who has been embattled by doubts of some shareholders over her ability to lead the pharmaceutical business, spent a significant portion of 2021 highlighting the planned demerger and preparing shareholders for the future of GSK.

Since taking over the helm of GSK in 2017, Walmsley has been positioning the company's pharma platform for future growth. Over the past five years, the company has achieved 13 major regulatory approvals and has a pipeline of more than 60 different assets, including 23 potential vaccines for various viral threats.

"We are now ready to deliver the most significant corporate change for GSK seen in more than 20 years, to separate and create a new GSK and new consumer healthcare. Both of these businesses will have scale impacts on human health and the opportunity to deliver compelling performance attractive returns to shareholders," Walmsley said in her presentation.

The de-merger is expected to take place in the middle months of 2022.

Dunnie et al

https://investors.vir.bio/static-files/08bc6665-d0a9-4e86-b746-35ad88fa0235

https://www.youtube.com/watch?v=eOU7_mw-o4A

VIR will make 2 million in the first half of 2022 and further 3 million in second half of 2022 that is revenue of $12 billion

Share price is 28% over priced- the debt will take 5 years to clear if they were at full capacity- over hyped and investors will get badly burnt - all airline and travel stocks in Tui-Jet2 are being manipulated by markets

Its 600,000 doses to the USA @$2500 per dose
https://www.marketwatch.com/press-release/gsk-and-vir-biotechnology-announce-united-states-government-agreement-to-purchase-additional-supply-of-sotrovimab-authorized-for-the-early-treatment-of-covid-19-2022-01-11?mod=mw_quote_news_seemore

https://www.limaohio.com/news/492438/monoclonal-antibodies-in-short-supply-due-to-omicron

VIr entered confidentiality agreements with countries on orders of Sotrovimab.I would assume the 2 half of 2021 and first half of 2022 will provide that info Dunnie- after all this is not the Pfizer BS show..

Dunnie.

A couple of things that Sotrovimab =Exudy as in its as – that no other Antiviral , mAb or Vaccine is its long term protection.

Once given , Sotrovimab is a long term protection- in the UA-Singpore-Japan-Australia its found every person given Sotrovimab still have 91% protection to all variants- so 10 months in – its actually as a better (EV) EFFICACY than any vaccine.
In Singapore they are scaling up to give more people Sotrovimab , and cut back on vaccines in all those people who have had repeated Hospital visits with Covid 19.

In the UAE- not one person out of 6134 who first received it in June- July of 2021 have contacrted Covid 19

VIR have now demonstrated Sotrovimab is effective against every Variant- furthermore it comeplety neutralized Delta and Delta plus and now Omicron- in Brazil it was used against Gamma- Lambda – Mu when given to patients with these 3 variants.

To-date not one other mAb as demonstrated it can neutralize Omicron- and AZN Evusheld failed against the common Variants and was waved through trials with little or no data to support it.

Eli Lilly mAb the EU refused to give an EUA to, as Eli Lilly did not provide data the EU EMA required in 8 months of Asking .

Sotrovimab is still the only Monoclonal Antibody that was in trials in 12 countries and showed it cut Deaths by 89% and Hospitalizations’ at 79.6% .

No problems Denby- I am use to the avatar who as no idea.
Of course those who buy anything for a few weeks can turn any figures in.
$16 IPO- Now $34. Contract to supply just 20,000 doses of Xeudy yesterday was worth $50 million- which GSK get approx 30% - its the only GSK Covid income.
When VIR turn over more in one treatment that GSK do from all there vaccines and GSK earn more for VIR Sotrovimab than they do out of there entire covid and CHG - suspect the usual suspect will be whinging.
VIR will earn GSK $ 4 billion per year .
Some come on hear to create noise and never offer anything of substance,- like AZN

papucel you are a complete fool.
I brought VIR at $16 and $52.
GSK invested $250 million in VIR shares - now who is the idiot here, as todate GSK only revenue from Covid 19 is from VIR.
Stop being a key board bandit and rook- you are so bad that Admin need to remove your other Avatars as well.

VIR have created a treatment to clear up Astra vaccine and Moderna vaccine failure .

If I am wrong to his the GSK Board of directors

We provide a blueprint of the OmicronVariant spike RBD mutations explaining the marked dampening of binding of all therapeutic mAbs, leading to reduced neutralizing activity, except for S309/sotrovimab that has 2-3x reduced binding/neutralization

https://www.biorxiv.org/content/10.1101/2021.12.28.474380v1

https://amgreatness.com/2021/12/29/doctors-outraged-after-biden-regime-shuts-down-life-saving-monoclonal-antibody-treatments/

https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-new-research-describing-structural

papucel You are a real clueless idiot of the highest dergree.
AZN have nothing of use there mAbs fail against Delta and Omicron.

You have no idea about Vir, and you are so far out of your depth.
Its the only treatment that as neutralized every variant.
Biden stopped it and Covid Omicron ran amok ...
GSK have approx 30% of its revenue from Sotrovimab,.
Share price is shorted by Pfizer and Pfizer are doing everything to stop Biden using Sotrovimab, as it shows Pfizer Vaccine like Astra do not have 95% EV they can not ma mange 50% and both fail after 16 days against Omicron

papucel, I suggest you report this to your buddy at admin, as you are clueless, and spout crap. VIR do not do what Pfizer or astra do and make claims, they just deliver the best and the Share price wil be determined on earned income per quarter, the shorting and bad mouthing by pfzier and other against GSK VIR, show how desperate they are
https://www.dailymail.co.uk/news/article-10350903/Texas-New-York-hospitals-run-antibody-treatment-effective-against-omicron-variant.html

https://www.dailymail.co.uk/news/article-10350903/Texas-New-York-hospitals-run-antibody-treatment-effective-against-omicron-variant.html

S309 = VIR 7831/7832 Sotrovimab. S309 is the antibody that survivors from Sars 2 in China year 2003 immune system created itself.. Why GSK VIR have the only treatment and why the UK wont admit is vaccine policy failed and it buying antivirals is tied to its failure on Covid 19.. Johnson should be embracing GSK Vir and where is Sajid Javed ?? he is still counting his bungs from Pfizer .. Omicron break down on link below
https://twitter.com/veeslerlab/status/1476953875781283841